Overview

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab